Kang J, Compton DR, Vaz RJ, et al. Proarrhythmic mechanisms of the common antidiarrhealmedication loperamide: Revelations from the opioid abuse epidemic. NaunynSchmiedeberg's Arch Pharmacol 2016;389:1133-1137.
Eggleston W, Marraffa JM, Stork CM, et al. Notes from the field: cardiac dysrhythmias after loperamide abuse — New York, 2008-2016. Morb Mortal Wkly Rep.2016;65(45):1276–1277.
Miller H, Panahi L, Tapia D, et al. Loperamide misuse and abuse. J Am Pharm Assoc.2017;57:S45–S50.
Eggleston W, Marraffa JM, Stork CM, et al. Notes from the field: cardiac dysrhythmias after loperamide abuse — New York, 2008-2016. Morb Mortal Wkly Rep.2016;65(45):1276–1277.
Lasoff DR, Koh CH, Corbett B, et al. Loperamide trends in abuse and misuse over 13 years: 2002-2015. Pharmacotherapy. February 2017;37(2):249–253. doi: 10.1002/phar.1885.
Miller H, Panahi L, Tapia D, et al. Loperamide misuse and abuse. J Am Pharm Assoc.2017;57:S45–S50.
Larsen TR, McMunn J, Ahmad H, et al. Ventricular Tachycardia Triggered by Loperamide and Famotidine Abuse. Drug Saf – Case Rep. 2018;5:11. https://doi.org/10.1007/s40800-018-0077-0.
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits packaging for anti-diarrhea medicine loperamide (Imodium) to encourage safe use. January 31, 2018. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm594232.htm. Accessed on January 30, 2018.
